Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Summary

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Timeline

Start

2023-10-03

Primary completion

2032-02-22

Completion

2032-02-22

Drugs

Indications